@article{WohlfarthSchmitteckertHaertleetal.2017,
  author    = {Wohlfarth, Carolin and Schmitteckert, Stefanie and H{\"a}rtle, Janina D. and Houghton, Lesley A. and Dweep, Harsh and Fortea, Marina and Assadi, Ghazaleh and Braun, Alexander and Mederer, Tanja and P{\"o}hner, Sarina and Becker, Philip P. and Fischer, Christine and Granzow, Martin and M{\"o}nnikes, Hubert and Mayer, Emeran A. and Sayuk, Gregory and Boeckxstaens, Guy and Wouters, Mira M. and Simr{\´e}n, Magnus and Lindberg, Greger and Ohlsson, Bodil and Schmidt, Peter Thelin and Dlugosz, Aldona and Agreus, Lars and Andreasson, Anna and D'Amato, Mauro and Burwinkel, Barbara and Bermejo, Justo Lorenzo and R{\"o}th, Ralph and Lasitschka, Felix and Vicario, Maria and Metzger, Marco and Santos, Javier and Rappold, Gudrun A. and Martinez, Cristina and Niesler, Beate},
  title     = {miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome},
  series = {Scientific Reports},
  volume    = {7},
  journal   = {Scientific Reports},
  doi       = {10.1038/s41598-017-13982-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173478},
  year      = {2017},
  abstract  = {Irritable bowel syndrome (IBS) is a gut-brain disorder involving alterations in intestinal sensitivity and motility. Serotonin 5-HT4 receptors are promising candidates in IBS pathophysiology since they regulate gut motor function and stool consistency, and targeted 5-HT4R selective drug intervention has been proven beneficial in subgroups of patients. We identified a single nucleotide polymorphism (SNP) (rs201253747) c.*61 T > C within the 5-HT4 receptor gene \(HTR4\) to be predominantly present in diarrhoea-IBS patients (IBS-D). It affects a binding site for the miR-16 family and miR-103/miR-107 within the isoforms \({HTR4b/i}\) and putatively impairs \(HTR4\) expression. Subsequent miRNA profiling revealed downregulation of miR-16 and miR-103 in the jejunum of IBS-D patients correlating with symptoms. \(In\) \(vitro\) assays confirmed expression regulation via three 3′UTR binding sites. The novel isoform \(HTR4b\_2\) lacking two of the three miRNA binding sites escapes miR-16/103/107 regulationin SNP carriers. We provide the first evidence that \(HTR4\) expression is fine-tuned by miRNAs, and that this regulation is impaired either by the SNP c.*61 T > C or bydiminished levels of miR-16 and miR-103 suggesting that \(HTR4\) might be involved in the development of IBS-D.},
  language  = {en}
}
@article{SchmitterBoemickeBehnischetal.2022,
  author    = {Schmitter, Marc and B{\"o}micke, Wolfgang and Behnisch, Rouven and Lorenzo Bermejo, Justo and Waldecker, Moritz and Rammelsberg, Peter and Ohlmann, Brigitte},
  title     = {Ceramic crowns and sleep bruxism: first results from a randomized trial},
  series = {Journal of Clinical Medicine},
  volume    = {12},
  journal   = {Journal of Clinical Medicine},
  number    = {1},
  issn      = {2077-0383},
  doi       = {10.3390/jcm12010273},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-301480},
  year      = {2022},
  abstract  = {Background: This randomized clinical trial was conducted to assess whether sleep bruxism (SB) is associated with an increased rate of technical complications (ceramic defects) in lithium disilicate (LiDi) or zirconia (Z) molar single crowns (SCs). Methods: Adult patients were classified as affected or unaffected by SB based on structured questionnaires, clinical signs, and overnight portable electromyography (BruxOff) and block randomized into four groups according to SB status and crown material (LiDi or Z): LiDi-SB (n = 29), LiDi-no SB (n = 24), Z-SB (n = 23), and Z-no SB (n = 27). Differences in technical complications (main outcome) and survival and success rates (secondary outcomes) one year after crown cementation were assessed using Fisher's exact test with significance level α = 0.05. Results: No technical complications occurred. Restoration survival rates were 100\% in the LiDi-SB and LiDi-no SB groups, 95.7\% in the Z-SB group, and 96.3\% in the Z-no SB group (p > 0.999). Success rates were 96.6\% in the LiDi-SB group, 95.8\% in the LiDi-no SB group (p > 0.999), 91.3\% in the Z-SB group, and 96.3\% in the Z-no SB group (p ≥ 0.588). Conclusions: With a limited observation time and sample size, no effect of SB on technical complication, survival, and success rates of molar LiDi and Z SCs was detected.},
  language  = {en}
}